Principal Financial Group
OVID icon

Principal Financial Group’s Ovid Therapeutics OVID Stock Holding History

Principal Financial Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,598
Closed -$42K – 2598
2021
Q3 		$42K Sell
12,598
-2,043
-14% -$7.45K ﹤0.01% 2543
2021
Q2 		$57K Buy
14,641
+566
+4% +$2.23K ﹤0.01% 2564
2021
Q1 		$57K Sell
14,075
-10,544
-43% -$35K ﹤0.01% 2453
2020
Q4 		$57K Buy
+24,619
New +$115K ﹤0.01% 2385

Other funds holding OVID

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Principal Financial Group's OVID Position: Q4 2021 in Review

Principal Financial Group sold out of Ovid Therapeutics (OVID) in Q4 2021, closing a stake of 12,598 shares — an estimated $42K sold.

Principal Financial Group first reported a position in OVID in Q4 2020 and held it in 4 quarters. The position peaked at $57K in Q2 2021. 67 funds tracked by Wall St. Rank hold OVID as of Q4 2021.

  • Principal Financial Group reported no remaining Ovid Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Principal Financial Group sold 12,598 Ovid Therapeutics shares in Q4 2021, an estimated $42K.
  • Principal Financial Group first reported a position in Ovid Therapeutics in Q4 2020 and held it in 4 quarters.
  • Principal Financial Group's Ovid Therapeutics position peaked at $57K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.